Intestinal Barrier Impairment and Immune Activation in HIV-Infected Advanced Late Presenters are Not Dependent on CD4 Recovery

Archivum Immunologiae Et Therapiae Experimentalis
Kamila Wójcik-CichyElżbieta Jabłonowska

Abstract

Damage of the mucosal barrier in HIV infection, microbial translocation, and immune activation can persist even in patients on successful antiretroviral therapy (ART) especially advanced late presenters. The aim of this study was to find factors that determine immune activation and bacterial translocation in HIV-infected advanced late presenters on suppressive ART. Forty-three late presenters (CD4 < 200 cells/µl prior to ART) on successful ART (more than 2 years of ART) with optimal and suboptimal CD4 recovery were enrolled into this study. The serum concentrations of intestinal fatty acid-binding peptide (I-FABP), zonulin-1, programmed cell death-1 protein (PCDP-1), and soluble (s)CD14 were measured using the ELISA test. We found higher serum levels of I-FABP and sCD14 in successfully antiretroviral-treated advanced late presenters compared to healthy subjects (p < 0.0001 and p = 0.0004). The serum concentration of PCDP-1 and zonulin-1 in HIV-infected patients did not differ from healthy controls. The levels of microbial translocation and immune activation markers were not associated with the degree of CD4 recovery. A serum concentration of I-FABP above 2.03 ng/ml was independently associated with a shorter ART (OR 0.78; p = 0...Continue Reading

References

Sep 15, 2004·The Journal of Experimental Medicine·Jason M BrenchleyDaniel C Douek
Aug 19, 2006·Nature Medicine·Lydie TrautmannRafick-Pierre Sekaly
Sep 20, 2006·Annals of Internal Medicine·Judith E SackoffLucia V Torian
Mar 29, 2007·The Journal of Experimental Medicine·Zhifeng SunJ Victor Garcia
Jan 15, 2008·Current Opinion in Infectious Diseases·Martin Fisher
Oct 24, 2008·PLoS Medicine·Lewis H KullerUNKNOWN INSIGHT SMART Study Group
Feb 6, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Colleen F KelleySteven G Deeks
Jun 22, 2010·HIV Medicine·A AntinoriUNKNOWN European Late Presenter Consensus Working Group
Aug 12, 2010·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Amanda MocroftUNKNOWN EuroSIDA Study Group
Jan 12, 2011·The Journal of Infectious Diseases·Robert C KaplanSteven G Deeks
Jan 22, 2011·The Journal of Infectious Diseases·Netanya G SandlerUNKNOWN INSIGHT SMART Study Group
Feb 12, 2011·AIDS Research and Human Retroviruses·Gabriella d'EttorreVincenzo Vullo
Sep 16, 2011·The Journal of Infectious Diseases·Michael M LedermanBenigno Rodriguez
Nov 18, 2011·AIDS·Fumiyo NakagawaAndrew N Phillips
Apr 5, 2012·Clinical & Developmental Immunology·Julie C GaardboSusanne D Nielsen
Jan 17, 2013·The Journal of Infectious Diseases·Gema Méndez-LagaresManuel Leal
Aug 7, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Gaëlle BretonRafick-Pierre Sékaly
Oct 25, 2013·Lancet·Steven G DeeksDiane V Havlir
May 30, 2014·Current Opinion in HIV and AIDS·Hongyin Wang, Donald P Kotler
Jul 16, 2014·Journal of Immunology Research·Joshua J AnzingerClovis S Palmer
Feb 6, 2016·Current Opinion in HIV and AIDS·Victor Appay, Anthony D Kelleher
Mar 15, 2016·Seminars in Respiratory and Critical Care Medicine·Keith SigelKristina Crothers
Jul 9, 2016·Clinical Science·Morgane GriesbeckMarcus Altfeld
Jul 4, 2017·AIDS Research and Human Retroviruses·Maximilian MuenchhoffMohendran Archary

❮ Previous
Next ❯

Methods Mentioned

BETA
enzyme-linked immunosorbent assays
ELISA
flow cytometry

Software Mentioned

WorkOut

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis